News

CDMO’s goal is to increase building’s aseptic manufacturing capacity.

CDMO will financially commit $10.6 million toward semi-solid and non-sterile liquid production.

Deal includes Krazati, a therapy for patients with non-small cell lung cancer.

HDA research reveals that 95% of pharma transactions move through the traditional distribution channel.

CDMO’s Heidelberg facility will house the newly-completed manufacturing line.

Acquisition helps expand pharma marketing reach and opens door for growth opportunities.

Packaging manufacturers partner up in effort to help tackle pharma’s demand for recyclable packaging.

Site aims to advance regenerative medicines on a global scale.

The conference will focus on the full breadth of commercialization strategies and operations.

Purchase allows company to provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry.

Boehringer Ingelheim’s unbranded adalimumab-adbm biosimilar will be available at an 81% discount to adalimumab (Humira).

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

Exec joins the organization with decades of biopharma experience.

Statistics shows it up 1.5%, representing first annual growth since February 2022

Pharmaceutical product distributor continues goal of delivering safe and affordable medication to patients.

CTDMO is reportedly the first to provide this aforementioned service, which spans through commercialization.

Shares expected to be offered on Six Swiss Exchange.

Abrysvo reportedly reduces risk of condition in baby by 57% in the first six months after birth.

CDMO purchases branded sachet-packaging machine for commercial manufacturing.

The insulated shipping containers can be used in the pharma industry and are reportedly environmentally friendly.

This would signify an 8.3% CAGR over the next five years.

Company brings aboard former Pfizer exec as life sciences COO in effort to help further improve patient outcomes.

An analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistencies on the prices of both generics and branded products.

Project to focus on improving access to EstroGel.

Deal to focus on development and commercialization in key emerging countries.

Deal aims to provide diabetes treatment to patients across the continent.

Nearly 96% of respondents say that this is an issue affecting their respective pharmacy.

Expansion is expected to meet the growing market demand from the region.